• Filter by age:
  • all adults (15-64) |
  • young adults (15–34) |
  • youngest adults (15–24)
• Filter by gender:
  • females |
  • males
• Filter by prevalence:
  • last 30 days |
  • lifetime |
  • last 12 months
• Filter by drug type:
  • amphetamines |
  • cannabis |
  • cocaine |
  • ecstasy

Statistics found here the category is General population surveys of drug use (GPS)

Category	Title
GPS	GPS-1. Last 12 months prevalence of cannabis use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15- to 24-year-old age group, measured by national population surveys
GPS	GPS-2. Continuation rates of cannabis use (last 12 months and last 30 days use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-3. Last 30 days prevalence of cannabis use among the 15-to 24-year old age group, measured by national surveys
GPS	GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15 to 34), measured by national surveys Part (i) All countries
GPS	GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15 to 34), measured by national surveys Part (ii) Countries with three or more surveys
GPS	GPS-5. Last 12 months prevalence of amphetamines use among young adults aged 15 to 34 and 15 to 24, measured by population surveys
GPS	GPS-6. Last 12 months prevalence of amphetamines use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
GPS	GPS-7. Last 30 days prevalence of cannabis use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
GPS	GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group Part (i) All Member States with available information
GPS	GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group Part (ii) Males 15 to 24 in Member States with higher prevalence rates
GPS	GPS-10. Last 12 months prevalence of cannabis use by age group in United Kingdom (E&W), measured by national population surveys
GPS	GPS-11. Continuation rates of ecstasy (last 12 months and last 30 days use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-12. Last 12 months prevalence of cannabis use by age group in some Member States, measured by national population surveys — last survey available Part (i) Last 12 months prevalence in some of the EU-15 Member States
GPS	GPS-12. Last 12 months prevalence of cannabis use by age group in some Member States, measured by national population surveys — last survey available Part (ii) Last 12 months prevalence in some ‘new’ EU Member States
GPS	GPS-13. Last 12 months prevalence of cocaine use among all young adults (aged 15 to 34) by gender, measured by national surveys
GPS	GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-15. Last 12 months prevalence of cocaine use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
GPS	GPS-16. Continuation rates of cocaine use (last 12 months and last 30 days use among lifetime users) in the general population, measured by national surveys
GPS	GPS-17. Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34)
GPS	GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (i) Cannabis use — lifetime experience, last 12 months and last 30 days prevalence
GPS	GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (ii) Cocaine, amphetamines and ecstasy use — lifetime experience, last 12 months and last 30 days prevalence
GPS	GPS-20. Lifetime and last 12 months prevalence of cocaine use among young adults (aged 15 to 34) in Europe, Canada, Australia and the USA — last survey available for each country
GPS	GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-22. Continuation rates of amphetamines use (last 12 months and last 30 days use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (i) United Kingdom (E&W)
GPS	GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (ii) Denmark
GPS	GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (iii) Germany
GPS	GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (iv) Spain
GPS	GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (v) France
GPS	GPS-0. Nationwide surveys among the general population: Bibliographic references
GPS	GPS-1. Lifetime prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Survey methods: last survey available for each Member State (from 2000 onwards)
GPS	GPS-1. Lifetime prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Lifetime prevalence all adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-1. Lifetime prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Lifetime prevalence young adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-1. Lifetime prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iv) Lifetime prevalence 15 to 24 years old: last survey available for each Member State (from 2000 onwards)
GPS	GPS-2. Last 12 months prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Last 12 months prevalence all adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-2. Last 12 months prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Last 12 months prevalence young adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-2. Last 12 months prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Last 12 months prevalence 15 to 24 years old: last survey available for each Member State (from 2000 onwards)
GPS	GPS-3. Last 30 days prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Last 30 days prevalence all adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-3. Last 30 days prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Last 30 days prevalence young adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-3. Last 30 days prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Last 30 days prevalence 15 to 24 years old: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Lifetime prevalence all adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Lifetime prevalence all adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Lifetime prevalence young adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iv) Lifetime prevalence young adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (v) Lifetime prevalence 15 to 24 years old males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (vi) Lifetime prevalence 15 to 24 years old females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Last 12 months prevalence all adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Last 12 months prevalence all adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Last 12 months prevalence young adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iv) Last 12 months prevalence young adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (v) Last 12 months prevalence 15 to 24 years old males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (vi) Last 12 months prevalence 15 to 24 years old females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Last 30 days prevalence all adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Last 30 days prevalence all adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Last 30 days prevalence young adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iv) Last 30 days prevalence young adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (v) Last 30 days prevalence 15 to 24 years old males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (vi) Last 30 days prevalence 15 to 24 years old females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-7. Lifetime prevalence of drug use in nationwide surveys among the general population Part (i) Survey methods: all surveys
GPS	GPS-7. Lifetime prevalence of drug use in nationwide surveys among the general population Part (ii) Lifetime prevalence all adults: all surveys
GPS	GPS-7. Lifetime prevalence of drug use in nationwide surveys among the general population Part (iii) Lifetime prevalence young adults: all surveys
GPS	GPS-7. Lifetime prevalence of drug use in nationwide surveys among the general population Part (iv) Lifetime prevalence 15 to 24 years old: all surveys
GPS	GPS-8. Last 12 months prevalence of drug use in nationwide surveys among the general population Part (i) Last 12 months prevalence all adults: all surveys
GPS	GPS-8. Last 12 months prevalence of drug use in nationwide surveys among the general population Part (ii) Last 12 months prevalence young adults: all surveys
GPS	GPS-8. Last 12 months prevalence of drug use in nationwide surveys among the general population Part (iii) Last 12 months prevalence 15 to 24 years old: all surveys
GPS	GPS-9. Last 30 days prevalence of drug use in nationwide surveys among the general population Part (i) Last 30 days prevalence all adults: all surveys
GPS	GPS-9. Last 30 days prevalence of drug use in nationwide surveys among the general population Part (ii) Last 30 days prevalence young adults: all surveys
GPS	GPS-9. Last 30 days prevalence of drug use in nationwide surveys among the general population Part (iii) Last 30 days prevalence 15 to 24 years old: all surveys
GPS	GPS-10. Frequency of use of cannabis among all adults (aged 15 to 64 years) and young adults (aged 15 to 34 years) in nationwide surveys among the general population Part (i) Frequency of use among all users in last 30 days (percentage) — 2007 field trial
GPS	GPS-10. Frequency of use of cannabis among all adults (aged 15 to 64 years) and young adults (aged 15 to 34 years) in nationwide surveys among the general population Part (ii) Frequency of use among all users in last 30 days (percentage) — 2004 field trial
GPS	GPS-121. Methodological information for nation-wide surveys among the general population